Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
Key Financial Performance
Revenue for Q2 2025 $28 million, a decrease of $22 million year-over-year. The decline was primarily driven by lower revenues from the CSL collaboration reflecting lower supply agreement activity and amortization of the upfront payment as CoStave progresses toward global commercialization.
Revenue for H1 2025 $58 million, a decrease of $30 million year-over-year. The decline was primarily driven by lower revenues from the CSL collaboration reflecting lower supply agreement activity and amortization of the upfront payment as CoStave progresses toward global commercialization.
Total Operating Expenses for Q2 2025 $40 million, a decrease from $71 million year-over-year. The reduction was due to lower manufacturing costs for COVID, Flu, and Cystic Fibrosis programs, reduced clinical trial expenses for COVID and OTC, and lower payroll and employee benefits.
Total Operating Expenses for H1 2025 $86 million, a decrease from $139 million year-over-year. The reduction was due to lower manufacturing and clinical costs for the CoStave program, lower payroll and benefit expenses, and reduced facilities and equipment costs, partially offset by higher clinical expenses for the Cystic Fibrosis programs.
Research and Development Expenses for Q2 2025 $29.6 million, a decrease from $58.7 million year-over-year. The decrease was primarily driven by lower manufacturing costs for COVID, Flu, and Cystic Fibrosis programs, reduced clinical trial expenses for COVID and OTC, and lower payroll and employee benefits, partially offset by higher clinical costs for the CF program.
Research and Development Expenses for H1 2025 $64.5 million, a decrease from $112.2 million year-over-year. The decrease was primarily driven by lower manufacturing and clinical costs for the CoStave program, lower payroll and benefit expenses, and reduced facilities and equipment costs, partially offset by higher clinical expenses for the Cystic Fibrosis programs.
General and Administrative Expenses for Q2 2025 $10.3 million, a decrease from $12.3 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced headcount and employee benefits.
General and Administrative Expenses for H1 2025 $21.7 million, a decrease from $27.2 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced headcount and employee benefits.
Net Loss for Q2 2025 $9.2 million or $0.34 per diluted share, compared with a net loss of $17.2 million or $0.64 per diluted share year-over-year. The improvement was due to reduced operating expenses.
Cash, Cash Equivalents, and Restricted Cash as of June 30, 2025 $253.4 million, compared to $293.9 million as of December 31, 2024. The decrease reflects operational expenses and resource reallocation to the Cystic Fibrosis and OTC programs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ARCT-032: Advancing enrollment in Phase II trial for Cystic Fibrosis (CF) with daily inhaled treatments over 28 days. Completed enrollment and dosing of 5-mg cohort; progressing to 10-mg cohort. Interim data expected in September 2025. Phase III initiation planned for 2026.
ARCT-810: Positive interim data from Phase II studies for Ornithine Transcarbamylase (OTC) deficiency. Observed decreases in glutamine levels and stable ammonia levels. Preparing for Phase III trial design discussions with FDA in 2026.
CoStave (COVID-19 vaccine): Marketing authorization application filed in the UK; approval expected next month. NDA applications filed in Japan; approvals anticipated this fall. U.S. BLA filing on track for September 2025, with approval decision in 2026.
ARCT-2138: Phase I study for seasonal flu vaccine showed immunogenicity against all 4 influenza strains and no major safety concerns. Demonstrated potential for immune response in young and older adults.
ARCT-2304: Phase I trial for pandemic A/H5N1 influenza virus (bird flu) completed recruitment. FDA Fast Track designation received. Results expected later this year.
COVID-19 vaccine (CoStave): Progressing toward global commercialization with regulatory filings in the UK, Japan, and the U.S.
Restructuring Plan: Streamlined operations to focus on CF and OTC programs, extending cash runway into 2028. Significant reduction in operating expenses year-over-year.
Financial Performance: Revenue for Q2 2025 was $28M, down $22M from Q2 2024. Operating expenses reduced to $40M from $71M in Q2 2024. Net loss reduced to $9.2M from $17.2M in Q2 2024.
Pipeline Focus: Reallocated resources to prioritize CF and OTC programs, aligning with long-term strategic goals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The company anticipates meetings with the FDA and other regulatory agencies in 2026 to discuss Phase II data and plans for pivotal trials for ARCT-032 and ARCT-810. Regulatory approval timelines and outcomes are uncertain and could delay or impact the progression to Phase III trials.
Financial Risks: Revenue for Q2 2025 decreased by $22 million compared to the same period in 2024, primarily due to lower revenues from the CSL collaboration. This decline in revenue could impact the company's financial stability and ability to fund ongoing and future programs.
Operational Risks: The company is undergoing a restructuring plan and consolidating operations, which, while extending the cash runway into 2028, could pose risks related to operational efficiency and employee morale.
Market and Commercialization Risks: The transition of the CoStave program from development to commercialization has led to reduced revenues and lower manufacturing costs. The success of commercialization efforts remains uncertain and could impact future revenue streams.
Pipeline Development Risks: The ARCT-032 and ARCT-810 programs are still in early to mid-stage clinical trials. Any adverse safety or efficacy data could delay or halt development. Additionally, the success of these programs is critical as the company has streamlined its pipeline to focus on these areas.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ARCT-032 Program for Cystic Fibrosis: The company expects to provide Phase II interim data from the first 9 enrolled participants in September 2025. Completion of enrollment for the study is planned by year-end 2025. Meetings with the FDA and regulatory agencies are anticipated in the first half of 2026 to discuss Phase II data and plans for pivotal trials, including adolescent and pediatric participants, with Phase III initiation expected in 2026.
ARCT-810 Program for OTC Deficiency: The company is preparing for meetings with the U.S. FDA and other regulatory agencies to discuss the clinical significance of observed biomarker changes in relation to the design of the Phase III pivotal trial in pediatric studies. Phase III biomarker and trial design alignment with the FDA and other regulatory agencies is expected in the first half of 2026.
CoStave COVID-19 Vaccine: A marketing authorization application to the United Kingdom's MHRA was filed by CSL, with approval expected in September 2025. NDA applications were filed in Japan with anticipated approvals in fall 2025. A U.S. BLA filing to the FDA remains on track for September 2025, with an approval decision expected in 2026.
ARCT-2138 Seasonal Flu Vaccine: Results from a Phase I study demonstrated immunogenicity against all 4 influenza strains and tolerability at tested dose levels. No major safety concerns were raised. The study showed potential for inducing an immune response in both young and older adults.
ARCT-2304 Pandemic A/H5N1 Influenza Vaccine: The company received U.S. FDA Fast Track designation for ARCT-2304. Results from an ongoing Phase I study are expected later in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide a refresher on the bar for success in the CF trial and the ratio of modulator eligible to noneligible patients?
A:The FDA has set a 3% threshold for safety, tolerability, and positive measurable FEV as sufficient to proceed. Most of the 9 subjects enrolled are Class I (modulator nonresponders), with a strong majority being noneligible for modulators.
Q:What safety or efficacy data can you share on a blinded basis, and what work has been done on pivotal design alignment for OTC?
A:Arcturus has addressed toxicology and tolerability issues with innovations in delivery systems and purification processes. For OTC, the company has shared data with regulatory agencies and plans to meet with them to align on Phase III trial design, including the use of biomarkers.
Q:Will the highest dose data for CF be represented out to 28 days, and what is considered clinically meaningful?
A:Yes, 28-day data will be available for all 9 subjects, with some having data up to 56 days. A 3% FEV improvement is considered reasonable and clinically meaningful, especially for the challenging population targeted by this inhaled mRNA therapy.
Q:What is the interest level in patient enrollment after the Vertex and Moderna trial pause, and comments on the reopening of that trial?
A:Enrollment interest has been positively impacted in sites with overlap, but only a small number of sites overlap with competitors. The company does not speculate on competitors' trials but emphasizes its differentiated delivery technology and intellectual property.
Q:Do you plan to proceed to a higher dose cohort for CF, and what does preclinical data suggest about dose response?
A:The current plan includes a 15-milligram dose cohort. Preclinical data suggest a potential dose response, but a threshold response similar to modulators is also possible.
Q:How will FEV data be presented and interpreted, and are there additional measurements to enhance conviction in the program?
A:FEV data will be analyzed using area under the curve and baseline characteristics. Quality of life questionnaires are also being used to assess patient-reported outcomes.
Q:What is the timing of the end of Phase II meeting with the FDA for CF, and has it been delayed?
A:The end of Phase II meeting is expected in the first half of next year, with no additional trials anticipated before transitioning to Phase III in 2026.
Q:What is the rationale for the 15-milligram dose in the CF trial, and will there be additional data releases before FDA meetings?
A:The 15-milligram dose was agreed upon with the FDA based on prior Phase I and Ib data. Additional data releases for both CF and OTC programs are expected as Phase II trials are completed.
Q:What is the onset of action for the CF mRNA therapy, and how does it compare biologically?
A:The onset of action is relatively quick at the biochemical level, but biological effects, such as lung function improvement, may take weeks or months depending on the individual.
Q:What is the status of the U.S. BLA for COVID and the seasonal flu vaccine?
A:The U.S. BLA for COVID aims to approve the platform for the original multi-dose vial presentation, with annual updates expected. Seasonal flu vaccine data, including hemagglutinin response, will be shared later this year.
Q:When will fuller data for the OTC program be available, and will it include the higher dose cohort?
A:The timing depends on whether the 0.7 mg/kg cohort is included. If included, it will add a few months to the timeline. The company is also working on regulatory alignment for Phase III.
Q:How will the CF trial address the lack of a placebo arm, and will there be FEV1 data after the treatment period?
A:The Phase III trial will likely include a placebo arm. FEV1 data will be collected at day 56, 28 days after the treatment period ends, to assess treatment effects.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the potential impact of competitors' trials on their own program, stating it would be inappropriate to speculate. They also did not provide specific details on the timing of data releases for the seasonal flu vaccine and the higher dose cohort for the OTC program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CF participant
Co Research
CoStave
Cystic Fibrosis
Director
FDA agency
Fibrosis program
LLC Research
OTC program
Phase III
RNA candidate
Research Division
STARR vaccine
Securities LLC
cohort milligram
decrease manufacturing
dosing participant
employee benefit
enrollment
event
generation STARR
glutamine
influenza strain
level influenza
meeting FDA
month decrease
participant cohort
payroll
plan
runway summary
safety concern
ARCT Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary indicates a mixed sentiment. Strong product development updates and international expansion are positive, but lack of specific guidance and unclear management responses in the Q&A create uncertainty. No major catalysts like partnerships or guidance changes were noted, leading to a neutral prediction for stock movement.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call revealed strong financial performance with a significant increase in revenue and net income, driven by the mRNA platform and cost management. The increase in R&D expenses indicates ongoing investment in clinical trials, suggesting future growth potential. The operational cash flow also improved, supporting financial health. Despite some risks associated with forward-looking statements, the overall financial metrics and strategic investment in R&D provide a positive outlook for the stock price movement over the next two weeks.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Unknown8-11
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
ARCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
